BR112022012768A2 - Formulação de anticorpo de receptor 1 de morte celular programada e uso da mesma - Google Patents

Formulação de anticorpo de receptor 1 de morte celular programada e uso da mesma

Info

Publication number
BR112022012768A2
BR112022012768A2 BR112022012768A BR112022012768A BR112022012768A2 BR 112022012768 A2 BR112022012768 A2 BR 112022012768A2 BR 112022012768 A BR112022012768 A BR 112022012768A BR 112022012768 A BR112022012768 A BR 112022012768A BR 112022012768 A2 BR112022012768 A2 BR 112022012768A2
Authority
BR
Brazil
Prior art keywords
cell death
programmed cell
formulation
death receptor
antibody formulation
Prior art date
Application number
BR112022012768A
Other languages
English (en)
Inventor
Fang Yuan
Han Dongmei
Original Assignee
Shanghai Henlius Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Henlius Biotech Inc filed Critical Shanghai Henlius Biotech Inc
Publication of BR112022012768A2 publication Critical patent/BR112022012768A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

FORMULAÇÃO DE ANTICORPO DE RECEPTOR 1 DE MORTE CELULAR PROGRAMADA E USO DA MESMA. A presente invenção refere-se a uma formulação farmacêutica que contém um anticorpo monoclonal anti-PD-1. A formulação farmacêutica compreende um anticorpo monoclonal anti-PD-1, uma solução tampão de citratocitrato de sódio, um protetor de proteína, um tensoativo e um regulador isotônico. A presente invenção também se refere a uma aplicação da formulação farmacêutica na preparação de uma formulação líquida ou formulação liofilizada para injeção.
BR112022012768A 2020-01-06 2021-01-05 Formulação de anticorpo de receptor 1 de morte celular programada e uso da mesma BR112022012768A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010008058.6A CN110787292B (zh) 2020-01-06 2020-01-06 一种细胞程序性死亡受体1抗体制剂及其用途
PCT/CN2021/070248 WO2021139642A1 (zh) 2020-01-06 2021-01-05 一种细胞程序性死亡受体1抗体制剂及其用途

Publications (1)

Publication Number Publication Date
BR112022012768A2 true BR112022012768A2 (pt) 2022-09-06

Family

ID=69448561

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022012768A BR112022012768A2 (pt) 2020-01-06 2021-01-05 Formulação de anticorpo de receptor 1 de morte celular programada e uso da mesma

Country Status (10)

Country Link
US (1) US20230048612A1 (pt)
EP (1) EP4088740A4 (pt)
JP (1) JP2023510229A (pt)
KR (1) KR20220124208A (pt)
CN (1) CN110787292B (pt)
AU (1) AU2021205538A1 (pt)
BR (1) BR112022012768A2 (pt)
CA (1) CA3162976A1 (pt)
WO (1) WO2021139642A1 (pt)
ZA (1) ZA202207051B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110787292B (zh) * 2020-01-06 2020-04-24 上海复宏汉霖生物技术股份有限公司 一种细胞程序性死亡受体1抗体制剂及其用途
CN113797330A (zh) * 2020-06-11 2021-12-17 三生国健药业（上海）股份有限公司 一种抗pd-1单克隆抗体液体制剂
CA3180463A1 (en) * 2020-06-19 2021-12-23 Ping Hu Stable formulation for recombinant anti-pd-1 monoclonal antibody
MX2023001160A (es) * 2020-07-31 2023-02-22 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica del anticuerpo anti-pd-1 y uso del mismo.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106390115A (zh) * 2015-07-29 2017-02-15 上海君实生物医药科技股份有限公司 一种人源化单克隆抗体的稳定制剂
WO2018027524A1 (en) * 2016-08-09 2018-02-15 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibody formulation
EP4339615A3 (en) 2016-09-16 2024-05-22 Shanghai Henlius Biotech, Inc. Anti-pd-1 antibodies
CN109966487B (zh) * 2017-12-28 2023-08-25 上海复宏汉霖生物制药有限公司 一种包含抗pd-l1单克隆抗体的药物配制剂
CN110354073B (zh) * 2018-04-09 2021-10-01 鲁南制药集团股份有限公司 一种免疫抑制剂单克隆抗体的液体制剂
CN110787292B (zh) * 2020-01-06 2020-04-24 上海复宏汉霖生物技术股份有限公司 一种细胞程序性死亡受体1抗体制剂及其用途

Also Published As

Publication number Publication date
WO2021139642A1 (zh) 2021-07-15
CN110787292B (zh) 2020-04-24
CN110787292A (zh) 2020-02-14
AU2021205538A1 (en) 2022-07-14
JP2023510229A (ja) 2023-03-13
CA3162976A1 (en) 2021-07-15
ZA202207051B (en) 2023-11-29
EP4088740A4 (en) 2024-02-21
US20230048612A1 (en) 2023-02-16
KR20220124208A (ko) 2022-09-13
EP4088740A1 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
BR112022012768A2 (pt) Formulação de anticorpo de receptor 1 de morte celular programada e uso da mesma
EA201992377A1 (ru) Стабильная композиция антитела
AR111773A1 (es) Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración
BR112018002196A8 (pt) formulação anti-ifnar1 estável
HRP20120903T1 (hr) Tekuä†a formulacija koja sadrži visoku koncentraciju protutijela
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
BR112023015045A2 (pt) Agonistas de receptores de gpcr, composições farmacêuticas que compreendem os mesmos e métodos para seu uso
BR112017016636A2 (pt) formulação líquida estável para anticorpos monoclonais
BR112021013337A2 (pt) Proteínas de ligação a patógenos
AR117407A1 (es) Formulaciones acuosas estables de anticuerpos anti-tau
CL2023000004A1 (es) Formulación en concentración alta de proteínas de unión a antígeno del factor xii
BR112021023501A2 (pt) Formulações estabilizadas contendo anticorpos anti-angptl3
Mishra et al. Inhibition of mitochondrial division through covalent modification of Drp1 protein by 15 deoxy-Δ12, 14-prostaglandin J2
BR112022016456A2 (pt) Formulações de anticorpos anti-tslp humanos e métodos de uso dos mesmos
CO2021011648A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-il-33
Huang et al. Self-oligomerization is essential for enhanced immunological activities of soluble recombinant calreticulin
CL2023003218A1 (es) Polipéptidos de unión a antígeno bma031 mejorados
BR112023020621A2 (pt) Tratamentos para prurigo nodular
BR112023001471A2 (pt) Composição farmacêutica de anticorpo anti-pd-1 e uso da mesma
BR112021011290A2 (pt) Formulação de solução de proteína contendo alta concentração de um anticorpo anti-vegf
MX2023014616A (es) Formulaciones de anticuerpos anti-pd1.
BR112022022620A2 (pt) Formulações de anticorpos anti-il-33
Badar et al. Recombinant complement receptor 2 radiolabeled with [99mTc (CO) 3]+: a potential new radiopharmaceutical for imaging activated complement
Esponda et al. Post‐testicular change in the reptile sperm surface with particular reference to the snake, Natrix fasciata
Maňásková et al. Localization of porcine seminal plasma (PSP) proteins in the boar reproductive tract and spermatozoa